Abstract
Warby Parker Inc. will report second-quarter 2026 results on August 6, 2026 Pre-Market; this preview outlines consensus expectations for revenue, profitability, and EPS, and assesses the quarter’s key drivers including product innovation, mix, and operating leverage.
Market Forecast
Consensus points to second-quarter revenue of 237.75 million US dollars, up 11.55% year over year, with EBIT estimated at 14.78 million US dollars, up 37.21% year over year, and adjusted EPS forecast around 0.11, up 52.28% year over year. While no formal gross margin target is specified, the market expects margin dynamics to hinge on mix and pricing, following the company’s mid-50s gross margin performance last quarter and assuming stable input costs and promotional cadence.
The core eyeglasses products business remains the primary earnings engine; category highlights include recent assortment expansion and the April introduction of Warby Parker Sport performance eyewear, which supports average order value and frames-and-lenses attachment. The most promising adjacency is contact lenses—24.18 million US dollars last quarter—leveraging an increasingly recurring purchase pattern; company-wide revenue grew 8.34% year over year in the first quarter and is projected to rise 11.55% in the second quarter, reflecting improving momentum.
Last Quarter Review
Warby Parker Inc. delivered first-quarter revenue of 242.45 million US dollars (+8.34% year over year), a gross profit margin of 54.05%, GAAP net profit attributable to shareholders of 3.18 million US dollars with a 1.31% net profit margin, and adjusted EPS of 0.13 (-2.99% year over year).
A notable highlight was an outperformance versus consensus, with revenue exceeding expectations by 3.10 million US dollars and EPS surpassing estimates by 0.02, despite EBIT declining 10.55% year over year as the company invested through seasonal and macro variability.
Main business mix showcased the frame-and-lens foundation: eyeglasses products generated 201.44 million US dollars, contact lenses contributed 24.18 million US dollars, and eye care delivered 16.82 million US dollars; assortment breadth increased with the Warby Parker Sport performance line, priced from 195 US dollars.
Current Quarter Outlook
Core Eyeglasses Products and Retail Execution
The eyeglasses products category remains the central determinant of quarterly performance, given its role in driving both revenue and contribution profit. With consensus forecasting 237.75 million US dollars in revenue for the second quarter (+11.55% year over year), the implied setup anticipates healthy demand for frames-and-lenses, supported by price architecture and add-on lens upgrades. The recent launch of Warby Parker Sport in late April provides an incremental assortment lever that can nudge average order value without requiring deep promotional support, offering a favorable product mix impact in the quarter.
Sequentially, the revenue estimate reflects typical intra-year normalization from the first quarter’s 242.45 million US dollars run rate; what matters for profitability is whether unit demand and conversion sustain above last year’s comparable levels while discounting remains controlled. The eyeglasses category’s dynamics are sensitive to product mix—progressive, blue-light filtering, and thinner/higher-index lenses often carry better margins than basic prescriptions. The merchandising opportunity is to guide customers toward higher-value combinations that preserve a mid-50s gross margin profile even as the company attracts traffic with new collections and seasonal refreshes.
Operationally, retail execution should emphasize appointment availability, prescription capture, and cross-channel fulfillment that converts browsing into completed orders. For a vertically integrated retailer, the linkage between exam scheduling, lens fulfillment, and frame inventory positioning remains key to cycle times and customer satisfaction. Efficient routing of orders through labs and stores can reduce remake rates and expedite delivery, contributing directly to margin stability. In this backdrop, the double-digit year-over-year revenue growth forecast appears consistent with steady throughput, while EBIT expansion of 37.21% points to improved operating leverage as fixed costs absorb greater volume.
Product Innovation and Intelligent Eyewear Catalysts
Beyond the frame-and-lens core, product innovation is shaping expectations for the back half of the year. The partnership with Google and Samsung on Intelligent Eyewear, scheduled to debut in the fall, has become a meaningful sentiment driver, even if the revenue contribution for the second quarter will be negligible. Investor focus centers on how this initiative can expand the brand’s reach, attract new customers to the ecosystem, and catalyze cross-selling into traditional prescription products. The long-run value resides less in immediate unit economics and more in the ability to introduce new use cases that complement prescription eyewear, potentially increasing visit frequency and strengthening loyalty.
For the current quarter, the main way this catalyst affects financials is through marketing and engagement. As customer awareness builds, store traffic and digital curiosity may rise, creating opportunities to convert interest into standard eyewear purchases. The Warby Parker Sport performance line complements this narrative by broadening lifestyle applications—sports, outdoor, and active use—without deviating from the company’s core proposition of style, value, and prescription capability. In the near term, analysts will parse signals such as waitlists, sign-ups, or early marketing effectiveness to gauge how much incremental reach Intelligent Eyewear might generate when it launches.
From a profitability standpoint, Intelligent Eyewear’s early phases are likely to carry unknown gross margin and opex characteristics; however, the second quarter’s EBIT estimate growth of 37.21% year over year suggests that core operations are expected to hold or improve margins independent of this future initiative. This separation helps frame the quarter: investors can assess near-term earnings trajectory based on the existing product suite while treating Intelligent Eyewear as an option on customer acquisition and lifetime value. Coupled with ongoing product drops like Sport and the continued focus on premium lens attachments, the innovation roadmap provides a multi-quarter narrative that can support sustained engagement and, by extension, revenue growth.
Margins, Operating Leverage, and What Could Move the Stock
The stock’s reaction will likely track through three lenses: gross margin resilience, SG&A discipline, and evidence of operating leverage consistent with the step-up in EBIT growth. Last quarter’s gross margin of 54.05% set a solid baseline, aided by mix and pricing. For the second quarter, consensus does not provide a precise gross margin figure, but the path to meeting the EBIT estimate of 14.78 million US dollars depends on maintaining a favorable mix between frames, lenses, and higher-value add-ons while managing promotional intensity. If mix skews toward upgrades and specialty lenses, margin stability should follow; if promotional activity intensifies, gross margin could compress, requiring more SG&A efficiency to protect EBIT.
SG&A trajectory will be another focal point. The 52.28% year-over-year increase forecast for EPS implies that costs grow more slowly than revenue or that mix/efficiencies support margin uplift. Investors will look for signals of expense containment in areas such as marketing spend productivity and store-level operating efficiency. Fixed-cost leverage is inherently sensitive to sales volumes, so the double-digit revenue growth forecast is encouraging; however, any shortfall in top-line could be magnified in operating margin due to deleverage. Given last quarter’s 1.31% net profit margin and 3.18 million US dollars in net income, even modest improvements in gross margin and cost ratios can meaningfully impact EPS trajectory.
Two additional items could sway sentiment. First, the contact lens business, while smaller at 24.18 million US dollars last quarter, can provide recurring revenue that smooths volatility, and any evidence of improving subscription or reorder rates may be taken positively for visibility into the second half. Second, execution around service and eye care—16.82 million US dollars last quarter—matters for prescription capture and overall conversion, and thus for same-customer spend. While these adjacencies are not yet the largest profit pools, their ability to amplify core frames-and-lenses economics is a lever for both growth and margin integrity. Against this setup, achieving the 11.55% revenue growth and 37.21% EBIT growth forecasts would reinforce the narrative of operating leverage returning to the model, a combination that typically drives multiple support when delivered consistently.
Analyst Opinions
Bullish views dominate recent commentary, with a majority of published opinions positive versus neutral or hold-rated notes, reflecting a favorable backdrop for execution into the second quarter and beyond. Several well-followed institutions have reiterated constructive stances and raised or reaffirmed target prices in the upper-20s to low-30s range. The common threads in these bullish theses include confidence in mid-teens or better implied growth lanes for core eyewear, the incremental benefits from product innovation, and a line-of-sight to sustained margin expansion as operating leverage improves.
BTIG maintains a Buy rating with a 34 US dollars target, highlighting the AI-enabled Intelligent Eyewear opportunity as a structural catalyst for customer acquisition and differentiation. The firm’s stance effectively treats the fall launch as a brand amplifier that can enhance the top of funnel in the near term and expand addressable use cases over time, complementing the bread-and-butter prescription business. Telsey Advisory Group also reiterates Buy with a 32 US dollars price target, citing consistent execution and expectations for improving profitability as revenue growth compounds through mix and controlled promotions. Meanwhile, TD Cowen raised its target to 30 US dollars and reaffirmed Buy, emphasizing accelerating growth dynamics, product expansion, and a clearer path to profitability supported by scale benefits in SG&A and gross margin management. Bank of America’s Buy initiation with a 33 US dollars target adds to the positive consensus tone, underscoring confidence in demand durability and upcoming product catalysts.
Across these bullish takes, the analytical emphasis converges on the relationship between top-line momentum and operating leverage. With consensus modeling revenue of 237.75 million US dollars for the second quarter (+11.55% year over year), EBIT of 14.78 million US dollars (+37.21%), and EPS of 0.11 (+52.28%), bulls argue that the business is at an inflection where incremental volume can translate into outsized profit growth. They see product innovation—Warby Parker Sport now and Intelligent Eyewear in the fall—as a way to maintain customer engagement without structurally relying on discounting, thereby helping sustain gross margins around historical levels. They also point to the recurring nature of contact lens purchases and the eye care funnel as underappreciated contributors to revenue predictability and per-customer spend, which, combined with mix upgrades, can support earnings durability into the second half.
In summary, the prevailing institutional view is bullish: the quarter’s expectations are set at achievable levels, the revenue mix is tilting in constructive directions, and near-term catalysts offer multiple ways to reinforce the growth-and-margin narrative. Delivery in line with the projected 11.55% revenue growth and 37.21% EBIT growth would validate this stance, while any upside in gross margin or expense efficiency could yield positive EPS surprises against the 0.11 marker.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments